Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-discharge outcomes of fibroblast growth factor therapy in diabetic foot ulcer
ChiCTR2600134988Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant fibroblast growth factor in diabetic foot ulcer (DFU) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Incidence of first unplanned medical visit due to recurrent diabetic foot ulcer within 365 days after discharge. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
recombinant fibroblast growth factor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on ChiCTR2600134988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134988.